ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

SHANGHAI, July 23, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis....